Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADMANASDAQ:AXSMNASDAQ:NUVLNASDAQ:VERA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADMAADMA Biologics$20.81-3.7%$20.94$10.21▼$25.67$4.97B0.473.68 million shs2.77 million shsAXSMAxsome Therapeutics$104.10-2.0%$106.45$72.02▼$139.13$5.13B0.47677,321 shs425,883 shsNUVLNuvalent$78.24+0.4%$72.76$55.54▼$113.51$5.62B1.34492,596 shs364,260 shsVERAVera Therapeutics$22.74+1.0%$22.52$18.53▼$51.61$1.45B1.13949,096 shs1.31 million shs12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADMAADMA Biologics0.00%+0.97%+8.39%+12.91%+93.04%AXSMAxsome Therapeutics0.00%-6.98%-2.91%-14.61%+45.49%NUVLNuvalent0.00%+0.28%+10.20%+1.60%-2.23%VERAVera Therapeutics0.00%+0.18%+6.61%-18.76%-40.16%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADMAADMA Biologics2.347 of 5 stars2.61.00.00.02.82.51.9AXSMAxsome Therapeutics4.7317 of 5 stars4.52.00.04.52.44.20.6NUVLNuvalent2.1646 of 5 stars3.52.00.00.01.73.30.0VERAVera Therapeutics2.8876 of 5 stars4.61.00.00.02.62.50.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADMAADMA Biologics 3.25Buy$24.2516.53% UpsideAXSMAxsome Therapeutics 3.06Buy$172.3365.55% UpsideNUVLNuvalent 2.90Moderate Buy$115.5047.62% UpsideVERAVera Therapeutics 3.10Buy$65.00185.84% UpsideCurrent Analyst Ratings BreakdownLatest VERA, NUVL, AXSM, and ADMA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/12/2025AXSMAxsome TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$193.00 ➝ $186.006/10/2025AXSMAxsome TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.006/9/2025AXSMAxsome TherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$153.00 ➝ $150.006/3/2025VERAVera TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform6/3/2025VERAVera TherapeuticsGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy6/3/2025AXSMAxsome TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$185.006/2/2025VERAVera TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetSector Outperform ➝ Sector Outperform$55.00 ➝ $65.006/2/2025VERAVera TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$75.00 ➝ $85.005/22/2025AXSMAxsome TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$180.00 ➝ $180.005/14/2025AXSMAxsome TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/8/2025ADMAADMA BiologicsRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$25.00 ➝ $32.00(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADMAADMA Biologics$459.38M10.81$0.07 per share311.70$0.60 per share34.68AXSMAxsome Therapeutics$432.16M11.86N/AN/A$1.18 per share88.22NUVLNuvalentN/AN/AN/AN/A$10.94 per shareN/AVERAVera TherapeuticsN/AN/AN/AN/A$1.94 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADMAADMA Biologics-$28.24M$0.8574.3230.16N/A17.80%53.20%26.07%8/6/2025 (Estimated)AXSMAxsome Therapeutics-$287.22M-$5.77N/A36.91N/A-74.47%-223.51%-39.88%8/4/2025 (Estimated)NUVLNuvalent-$126.22M-$4.39N/AN/AN/AN/A-28.63%-27.15%8/14/2025 (Estimated)VERAVera Therapeutics-$95.99M-$3.00N/AN/AN/AN/A-50.13%-39.50%8/6/2025 (Estimated)Latest VERA, NUVL, AXSM, and ADMA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025NUVLNuvalent-$1.14-$1.18-$0.04-$1.18N/AN/A5/8/2025Q1 2025VERAVera Therapeutics-$0.75-$0.81-$0.06-$0.81N/AN/A5/7/2025Q1 2025ADMAADMA Biologics$0.16$0.14-$0.02$0.11$116.40 million$114.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADMAADMA BiologicsN/AN/AN/AN/AN/AAXSMAxsome TherapeuticsN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/AVERAVera TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADMAADMA Biologics0.487.093.26AXSMAxsome Therapeutics3.222.112.04NUVLNuvalentN/A23.0723.07VERAVera Therapeutics0.1713.7613.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADMAADMA Biologics75.68%AXSMAxsome Therapeutics81.49%NUVLNuvalent97.26%VERAVera Therapeutics99.21%Insider OwnershipCompanyInsider OwnershipADMAADMA Biologics3.50%AXSMAxsome Therapeutics22.30%NUVLNuvalent10.20%VERAVera Therapeutics16.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADMAADMA Biologics530238.73 million227.64 millionOptionableAXSMAxsome Therapeutics38049.24 million37.84 millionOptionableNUVLNuvalent4071.81 million62.16 millionOptionableVERAVera Therapeutics4063.77 million49.58 millionOptionableVERA, NUVL, AXSM, and ADMA HeadlinesRecent News About These CompaniesBrokers Offer Predictions for VERA FY2026 EarningsJune 13 at 2:57 AM | americanbankingnews.comWedbush Equities Analysts Raise Earnings Estimates for VERAJune 13 at 1:23 AM | americanbankingnews.comAnalysts Can't Get Enough of These Little-Known Biopharma Stocks (VERA)June 12 at 1:57 PM | marketbeat.comCantor Fitzgerald Comments on VERA FY2026 EarningsJune 11, 2025 | marketbeat.comQ2 EPS Estimates for Vera Therapeutics Increased by WedbushJune 11, 2025 | marketbeat.comVera Therapeutics Inc.June 10, 2025 | barrons.comVera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 9, 2025 | globenewswire.comVera Therapeutics (NASDAQ:VERA) Stock Price Down 5.2% - Here's What HappenedJune 9, 2025 | marketbeat.comOtsuka, Vera stake their claims to IgAN treatmentJune 9, 2025 | pharmaphorum.comResearch Analysts Offer Predictions for VERA FY2027 EarningsJune 7, 2025 | americanbankingnews.comOtsuka's kidney disease therapy trial results heat up battle with rival VeraJune 6, 2025 | msn.comVera Therapeutics (NASDAQ:VERA) Shares Gap Down - Should You Sell?June 6, 2025 | marketbeat.comBank of America Corp DE Sells 106,673 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)June 6, 2025 | marketbeat.comHC Wainwright Forecasts Lower Earnings for Vera TherapeuticsJune 6, 2025 | americanbankingnews.comWedbush Increases Earnings Estimates for Vera TherapeuticsJune 5, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Increases Position in Vera Therapeutics, Inc. (NASDAQ:VERA)June 5, 2025 | marketbeat.comVera Therapeutics (NASDAQ:VERA) Sees Strong Trading Volume After Analyst UpgradeJune 5, 2025 | americanbankingnews.comScotiabank Increases the Price Target for Vera Therapeutics by $10June 4, 2025 | msn.comVera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 4, 2025 | globenewswire.comVera Therapeutics Atacicept: Promising Step In IgAN, But Crowded Road Ahead (Rating Downgrade)June 4, 2025 | seekingalpha.comFY2025 EPS Estimate for Vera Therapeutics Lowered by AnalystJune 4, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueIntel’s Turnaround May Be the Best Bet No One’s WatchingBy Jeffrey Neal Johnson | May 30, 2025View Intel’s Turnaround May Be the Best Bet No One’s WatchingBullish NVIDIA Market Set to Surge 50% Ahead of Q1 EarningsBy Thomas Hughes | May 27, 2025View Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings5 Small-Cap Stocks to Watch for Big Speculative GainsBy Thomas Hughes | May 21, 2025View 5 Small-Cap Stocks to Watch for Big Speculative GainsVERA, NUVL, AXSM, and ADMA Company DescriptionsADMA Biologics NASDAQ:ADMA$20.81 -0.79 (-3.66%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$21.20 +0.39 (+1.85%) As of 06/13/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.Axsome Therapeutics NASDAQ:AXSM$104.10 -2.15 (-2.02%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$104.08 -0.02 (-0.02%) As of 06/13/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.Nuvalent NASDAQ:NUVL$78.24 +0.33 (+0.42%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$78.28 +0.04 (+0.04%) As of 06/13/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Vera Therapeutics NASDAQ:VERA$22.74 +0.22 (+0.98%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$22.73 -0.01 (-0.04%) As of 06/13/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones RH Stock Rockets on Surprise Profit and Tariff Shift Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
